Market Cap (In USD)
248.53 Million
Revenue (In USD)
388.15 Million
Net Income (In USD)
-174.23 Million
Avg. Volume
664.00
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 2.54-4.59
- PE
- -
- EPS
- -
- Beta Value
- 1.246
- ISIN
- AU000000MYX0
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Mr. Shawn Patrick O'Brien B.Sc
- Employee Count
- -
- Website
- https://www.maynepharma.com
- Ipo Date
- 2013-03-22
- Details
- Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. The company operates through four segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. It provides oral drug delivery systems; and contract pharmaceutical development, manufacturing, and analytical services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
More Stocks
-
RIGG
-
UBAAFUrbana Corporation
UBAAF
-
GODAVARIGodavari Drugs Limited
GODAVARI
-
ALPHAINDALPHALOGIC INDUSTRIES LIMITED
ALPHAIND
-
001820SAMWHA CAPACITOR Co.,LTD
001820
-
6939
-
PGD
-
BRBS